SCHEMBL1982855

SCHEMBL1982855

C=C(N)NC(CS)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.57
MAPT P10636 1/20 0.57
THRB P10828 1/20 0.57
ALOX15 P16050 1/20 0.57
NFKB1 P19838 1/20 0.57
PTGS2 P35354 1/20 0.57
THPO P40225 1/20 0.57
RECQL P46063 1/20 0.57
BLM P54132 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
ACE P12821 1/20 0.52
FOLH1 Q04609 1/20 0.48
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
TGFBR1 P36897 2/20 0.41
PTGS1 P23219 2/20 0.39
SLC7A11 Q9UPY5 1/20 0.39
FNTA P49354 2/20 0.36
FNTB P49356 2/20 0.36
ENPEP Q07075 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4606302 1.00 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL478268 0.82 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1289325 0.82 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL478269 0.82 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL9250416 0.82 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL13659830 0.78 MAPT (0.69) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL18306374 0.78 MAPT (0.69) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL9690433 0.78 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL2793250 0.78 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1998411 0.77 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366738-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE AGILENT TECHNOLOGIES INC (US) 2024-11-07 US disclosed
US-11992518-B2 Molecular vaccines for infectious disease AGILENT TECHNOLOGIES, INC. (US) 2024-05-28 US disclosed
US-11842798-B2 Natural product and genetic data analysis and discovery system, method and computational platform therefor ADAPSYN BIOSCIENCE INC. (CA) 2023-12-12 US disclosed
EP-3391260-B1 A NATURAL PRODUCT AND GENETIC DATA ANALYSIS AND DISCOVERY SYSTEM, METHOD AND COMPUTATIONAL PLATFORM THEREFOR ADAPSYN BIOSCIENCE INC (CA) 2023-08-23 EP disclosed
US-10968269-B1 MHC multimers in borrelia diagnostics and disease AGILENT TECHNOLOGIES, INC. (US) 2021-04-06 US disclosed
US-20210047383-A1 MHC Multimers in Borrelia Diagnostics and Disease DAKO DENMARK APS (DK) 2021-02-18 US disclosed
US-20200347103-A1 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS AGILENT TECHNOLOGIES INC (US) 2020-11-05 US disclosed
US-10611818-B2 MHC multimers in tuberculosis diagnostics, vaccine and therapeutics AGILENT TECHNOLOGIES, INC. (US) 2020-04-07 US disclosed
US-20190314471-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE AGILENT TECHNOLOGIES, INC. 2019-10-17 US disclosed
US-10369204-B2 Molecular vaccines for infectious disease DAKO DENMARK A/S (DK) 2019-08-06 US disclosed
EP-2337795-A2 MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING Dako Denmark A/S (DK) 2011-06-29 EP disclosed
EP-2254592-A2 MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE Dako Denmark A/S (DK) 2010-12-01 EP disclosed
EP-2197908-A2 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS Dako Denmark A/S (DK) 2010-06-23 EP disclosed
WO-2010037402-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2010037397-A1 MHC MULTIMERS IN CMV IMMUNE MONITORING DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2010037395-A2 MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2009106073-A2 MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE DAKO DENMARK A/S (DK) 2009-09-03 WO disclosed
WO-2009039854-A2 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS DAKO DENMARK A/S (DK) 2009-04-02 WO disclosed
US-7358076-B2 Sublancin lantibiotic produced by Bacillus subtilis 168 THE UNIVERSITY OF MARYLAND (US) 2008-04-15 US disclosed
US-20030166835-A1 Sublancin lantibiotic produced by Bacillus subtilis 168 UNIVERSITY OF MARYLAND 2003-09-04 US disclosed